VRTX

VertexB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$585.00

Analysis reference price unavailable

Analysis 2026-10-14 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$510.00

Analysis reference price unavailable

Analysis 2026-10-14 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$400.00

Analysis reference price unavailable

Analysis 2026-10-14 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-14

AI commentary

Company news includes supportive September renal-program and October ALYFTREK updates, while the packet's recent market coverage is thin. The October 13 anchor is $485.22; no verified post-event price-reaction series or analyst target revisions were supplied. Zero-valued sentiment fields denote unavailable measurements, not neutral observations.

RankAlpha Sentiment Codex - 2026-10-14

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-11-02eventCrinetics economics in the November 2 resultsMedium impact

Vertex has scheduled its third-quarter results for November 2. Its September 1 announcement confirmed the Crinetics acquisition closed; the report may clarify acquisition accounting, integration spending and the effect on guidance, none of which is established by the scheduling announcement. The August release raised standalone 2026 revenue guidance to $13.1 billion–$13.2 billion. [#PR-EARNINGS-2026-10-07] [#SEC-8K-2026-08-03] [#8-K-2026-09-01] https://investors.vrtx.com/news-releases/news-release-details/vertex-completes-acquisition-crinetics-pharmaceuticals-and

2026-11-30eventPovetacicept IgAN FDA decisionHigh impact

The FDA assigned November 30 as the target action date for the accelerated-approval application. Approval could establish Vertex's first commercial nephrology therapy; a delay, restrictive label or rejection would undermine that expansion. [#SEC-8K-2026-08-03] [#IR-2026-06-01] https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-us-fda-acceptance-biologics-license-application

2027-10-14catalystInaxaplin AMPLITUDE interim analysisHigh impact

Vertex says AMPLITUDE enrollment is complete and expects interim results in early 2027; positive pivotal data could support a potential accelerated-approval filing for APOL1-mediated kidney disease. The September AMPLIFIED results concern additional populations and do not establish pivotal efficacy. [#IR-2026-09-22] https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-14 • Updated nightlySource: Internal modelMethodology